Archit Organosys (BSE 524640)₹69.02−2.79%Commodity Chemicals
In the Mar 2026 quarter (standalone), Archit Organosys reported sales of ₹36.49 Cr, down 15.4% from Mar 2025, and net profit of ₹2.03 Cr, up 0.0% year on year. For the year to Mar 2026, sales were ₹141 Cr and net profit ₹8.03 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30.96 | 26.35 | 24.80 | 30.95 | 26.98 | 29.51 | 25.82 | 43.14 | 33.18 | 32.82 | 38.38 | 36.49 |
| Expenses | 27.81 | 24.31 | 23.74 | 30.77 | 23.98 | 26.72 | 23.26 | 38.81 | 29.12 | 30.22 | 33.78 | 31.67 |
| Operating Profit | 3.23 | 2.10 | 1.11 | 0.28 | 3.06 | 2.84 | 2.67 | 4.41 | 4.13 | 2.69 | 4.69 | 4.88 |
| OPM % | 10.5% | 8.0% | 4.5% | 1.0% | 11.4% | 9.7% | 10.4% | 10.3% | 12.6% | 8.3% | 12.3% | 13.5% |
| Other Income | 0.70 | 0.53 | 0.51 | 4.10 | 0.46 | 0.62 | 0.92 | 1.05 | 0.99 | 1.45 | 0.89 | −0.46 |
| Interest | 0.53 | 0.66 | 0.78 | 0.65 | 0.63 | 0.79 | 0.48 | 0.72 | 0.61 | 0.68 | 0.57 | 0.47 |
| Depreciation | 1.18 | 1.48 | 1.48 | 1.49 | 1.48 | 1.49 | 1.48 | 1.45 | 1.50 | 1.53 | 1.51 | 1.48 |
| Profit before tax | 2.25 | 0.52 | −0.65 | 2.29 | 1.42 | 1.21 | 1.64 | 3.32 | 3.06 | 1.98 | 3.51 | 2.48 |
| Tax % | 26.9% | 27.5% | −29.6% | 21.6% | 29.2% | 15.1% | 37.5% | 38.8% | 33.2% | 21.9% | 31.0% | 18.3% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 2.63 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 1.65 | 0.38 | −0.47 | 1.80 | 1.02 | 1.03 | 1.02 | 2.03 | 2.05 | 1.55 | 2.44 | 2.03 |
| EPS (Rs) | 0.81 | 0.19 | −0.23 | 0.88 | 0.50 | 0.51 | 0.50 | 0.99 | 1.00 | 0.76 | 1.19 | 0.99 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50.97 | 47.93 | 81.88 | 83.92 | 76.98 | 94.82 | 138 | 128 | 113 | 126 | 141 | 141 |
| Expenses | 48.08 | 44.08 | 78.14 | 87.15 | 73.13 | 83.10 | 121 | 108 | 106 | 113 | 125 | 125 |
| Operating Profit | 2.99 | 3.99 | 4.01 | −2.99 | 4.01 | 10.99 | 16.98 | 19.98 | 6.99 | 12.99 | 15.99 | 16.39 |
| OPM % | 6.0% | 8.1% | 4.6% | −3.6% | 4.6% | 12.1% | 12.1% | 15.0% | 6.1% | 10.0% | 12.1% | 11.6% |
| Other Income | 0.99 | 0.00 | 2.99 | 2.99 | 1.99 | 0.00 | 0.99 | 2.99 | 5.98 | 2.99 | 2.99 | 2.87 |
| Interest | 1.01 | 1.01 | 4.01 | 4.01 | 3.01 | 3.01 | 1.99 | 2.01 | 3.01 | 3.01 | 2.01 | 2.33 |
| Depreciation | 0.00 | 1.01 | 2.99 | 2.99 | 3.01 | 3.99 | 5.01 | 4.99 | 6.01 | 5.99 | 5.99 | 6.02 |
| Profit before tax | 2.01 | 3.01 | 0.00 | −6.01 | −1.01 | 5.01 | 11.01 | 15.01 | 4.01 | 8.01 | 11.02 | 11.03 |
| Tax % | 37.1% | 42.1% | −31.9% | −24.9% | 1.0% | −7.0% | 28.1% | 26.1% | 24.1% | 33.1% | 27.1% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.99 | 2.99 | 0.00 | 0.00 | 0.00 |
| Net Profit | 1.01 | 2.01 | 1.01 | −5.02 | −1.01 | 5.02 | 8.03 | 11.04 | 3.01 | 5.02 | 8.03 | 8.07 |
| EPS (Rs) | 0.98 | 1.15 | 0.35 | −3.15 | −0.54 | 3.35 | 4.02 | 5.58 | 1.64 | 2.47 | 3.92 | 3.94 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 15.0% | 19.0% | 9.0% | 0.0% | 0.0% | 26.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.00 | 5.01 | 10.03 | 15.03 | 15.03 | 15.03 | 15.03 | 21.04 | 21.04 | 21.06 | 21.05 | 21.05 |
| Reserves | 2.00 | 7.99 | 17.00 | 24.99 | 19.99 | 18.98 | 25.97 | 31.01 | 40.96 | 44.02 | 49.00 | 56.01 |
| Borrowings | 9.01 | 11.00 | 31.03 | 35.98 | 36.98 | 32.96 | 29.97 | 34.02 | 30.97 | 26.03 | 27.99 | 25.02 |
| Other Liabilities | 10.05 | 8.04 | 12.05 | 26.13 | 12.05 | 16.08 | 17.08 | 18.09 | 27.13 | 18.08 | 26.12 | 25.12 |
| Total Liabilities | 24.06 | 32.04 | 70.11 | 101 | 84.05 | 83.05 | 87.05 | 104 | 120 | 108 | 123 | 127 |
| Fixed Assets | 6.01 | 5.99 | 47.04 | 47.01 | 46.99 | 49.99 | 47.99 | 45.03 | 49.98 | 60.06 | 54.03 | 49.98 |
| CWIP | 0.00 | 8.01 | 1.01 | 8.01 | 5.01 | 1.01 | 3.01 | 13.02 | 14.01 | 1.01 | 1.01 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 4.01 | 6.01 | 6.02 | 7.02 |
| Other Assets | 18.05 | 18.04 | 22.06 | 46.11 | 32.05 | 32.05 | 37.05 | 44.10 | 52.10 | 42.11 | 62.10 | 70.20 |
| Inventories | 3.25 | 2.77 | 2.48 | 7.09 | 5.82 | 3.27 | 3.53 | 5.92 | 3.37 | 3.43 | 4.29 | 2.94 |
| Trade receivables | 11.63 | 11.07 | 11.35 | 31.40 | 14.38 | 19.74 | 25.02 | 27.40 | 37.40 | 22.27 | 23.08 | 24.57 |
| Cash & equivalents | 0.93 | 0.90 | 0.60 | 0.78 | 4.91 | 2.96 | 3.82 | 5.36 | 5.39 | 4.23 | 0.41 | 2.26 |
| Total Assets | 24.06 | 32.04 | 70.11 | 101 | 84.05 | 83.05 | 87.05 | 104 | 120 | 108 | 123 | 127 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 2.01 | 0.99 | 2.01 | −4.01 | 2.99 | 7.99 | 11.01 | 10.99 | 18.01 | 9.99 | 18.99 | 2.99 |
| Cash from investing activity | −2.01 | −8.01 | −35.03 | −9.01 | 1.01 | −1.01 | −3.01 | −12.01 | −12.01 | −2.01 | −21.01 | 4.01 |
| Cash from financing activity | 1.01 | 7.03 | 32.11 | 13.04 | 0.00 | −9.03 | −7.02 | 2.01 | −7.03 | −9.04 | −1.01 | −6.02 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 0.00 | 4.01 | −2.01 | 1.01 | 2.01 | 0.00 | −1.01 | −4.01 | 1.01 |
| Capex | 2.13 | 8.17 | 34.81 | 10.03 | 1.06 | 1.48 | 0.18 | 1.07 | 13.36 | 1.60 | 0.49 | 1.23 |
| Free cash flow | 0.00 | −6.98 | −31.89 | −12.96 | 2.99 | 5.98 | 7.98 | 0.00 | 8.97 | 14.95 | 17.94 | 0.99 |
| CFO / OP % | 93.1% | 57.1% | 75.1% | −89.9% | −96.9% | 221.1% | 99.1% | 71.1% | 108.1% | 164.1% | 150.1% | 30.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 77 | 80 | 87 | 141 | 63 | 95 | 98 | 73 | 108 | 73 | 68 | 65 |
| Inventory days | 28 | 28 | 27 | 41 | 30 | 22 | 21 | 22 | 16 | 16 | 18 | 11 |
| Days payable | 72 | 63 | 80 | 126 | 55 | 88 | 87 | 51 | 110 | 62 | 94 | 65 |
| Cash conversion cycle | 33 | 44 | 33 | 56 | 38 | 28 | 30 | 44 | 13 | 26 | −8 | 10 |
| Working capital days | −2 | 2 | 18 | 11 | −24 | −40 | −16 | 0 | 9 | 9 | 44 | 39 |
| ROCE % | 19.9% | 16.9% | 8.9% | 6.0% | −4.0% | 3.0% | 11.9% | 17.9% | 16.9% | 4.0% | 11.0% | 12.9% |
For the Mar 2026 quarter, Archit Organosys reported sales of ₹36.49 Cr, down 15.4% year on year and net profit of ₹2.03 Cr, up 0.0% year on year. The operating margin was 13.5%.
Archit Organosys' sales for the year to Mar 2026 were ₹141 Cr; over the last twelve months they were ₹141 Cr.
Net profit for the year to Mar 2026 was ₹8.03 Cr, and ₹8.07 Cr over the last twelve months. Earnings per share over the same trailing period were ₹3.94.
Archit Organosys reported borrowings of ₹25.02 Cr at Mar 2026, against cash and equivalents of ₹2.26 Cr.
Cash from operations was ₹2.99 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹0.99 Cr.